Bioequivalence of Tipranavir Storage Conditions

Phase 1, randomised, open-label trial of tipranavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 hours extrapolated to infinity up to 72 hours and Maximum measured concentration of the analyte in plasma up to 72 hours. Started May 2005; status: completed.